Nanjing Medlander Medical Technology Co.,Ltd. (SHA:688273)

SHA:688273 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	383.3	431.59	424.55	340.82	376.89	341.64
Revenue Growth	-12.37%	1.66%	24.57%	-9.57%	10.32%	1.52%
Gross Profit Gross Profit Growth	258.18	300.64	305.49	241.9	258.01	248.98
Operating Income Operating Income Growth	43.82	82.39	104.94	66.12	104.57	113.6
Net Income Net Income Growth	75.44	102.63	101.58	89.82	121.68	118.38
Earnings Per Share EPS Growth	0.77	1.05	1.03	0.90	1.46	1.58
EPS Growth	-18.67%	1.77%	14.77%	-38.49%	-7.49%	-2.92%

Revenue by Segment

Chart

Fiscal Year	FY 2025
Period Ending	Dec 31, 2025
Pelvic Floor Rehabilitation Pelvic Floor Rehabilitation Growth	160.01
Reproductive Rehabilitation Reproductive Rehabilitation Growth	127.11
Sports Rehabilitation Sports Rehabilitation Growth	8.76
Other Products Other Products Growth	1.64
Consumables and Accessories Consumables and Accessories Growth	122.31
Total Total Growth	419.82

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	723.07	816.45	894.98	1,097	1,216	272.62
Total Debt Total Debt Growth	35.74	26.42	10.6	8.51	9.43	6.22
Net Cash (Debt) Net Cash Growth	687.33	790.03	884.38	1,089	1,206	266.4
Net Cash Growth	-11.86%	-10.67%	-18.77%	-9.75%	352.86%	86.98%
Net Cash Per Share Net Cash Per Share Growth	7.03	8.08	8.98	10.89	14.48	3.55

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	66.53	105.43	122.51	136.91	126.67	148.6
Capital Expenditures CapEx Growth	-68.6	-118.15	-129.71	-75.15	-54.26	-14.58
Free Cash Flow Free Cash Flow Growth	-2.08	-12.73	-7.2	61.76	72.41	134.01
Free Cash Flow Growth	-	-	-	-14.71%	-45.97%	27.41%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	67.36%	69.66%	71.95%	70.97%	68.46%	72.88%
Operating Margin	11.43%	19.09%	24.72%	19.40%	27.74%	33.25%
Pretax Margin	18.18%	24.64%	29.47%	29.78%	38.71%	37.97%
Profit Margin	19.68%	23.78%	23.93%	26.35%	32.29%	34.65%
FCF Margin	-0.54%	-2.95%	-1.70%	18.12%	19.21%	39.23%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 4, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Dividend Per Share Dividend Per Share Growth	0.800	0.800	0.800	0.600	1.300
Dividend Per Share Growth	0%	0%	33.33%	-53.85%	-
Dividend Yield	2.73%	1.90%	3.54%	1.95%	4.41%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 4, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	37.49	40.52	22.51	37.32	26.79	-
Forward PE	-	12.43	12.43	21.56	-	-
P/FCF Ratio	-	-	-	54.27	45.02	-
PS Ratio	7.38	9.64	5.39	9.83	8.65	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error